



ASX & Media Release

Patrys Deoxymab Video Replacement

Melbourne, Australia; 18 October, 2017: Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company announced today the release of a video explaining how Deoxymab 3E10 targets tumors, and how by binding to DNA in the nucleus of cancer cells it causes cancer cell death.

The initial filing of this announcement contained an incorrect hyperlink. The correct hyperlink for accessing the video via the Patrys website follows: www.patrys.com.

“In recent weeks we have reported positive pre-clinical data from both the PAT-DX1 and the PAT-DX1-NP programs, and this has generated significant interest in these assets,” said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. “This video explains the current understanding of the mechanism of action of these first-in-class DNA damage response assets, highlighting the novelty and versatility of this technology both as a stand-alone therapeutic candidate and a tumor-targeting technology for conjugation to other molecules.”

About Deoxymab 3E10 and PAT-DX1

Patrys has a worldwide license to develop and commercialize as anti-cancer agents a portfolio of pre-clinical novel anti-DNA antibodies and antibody fragments/variants and antibody-nanoparticle conjugates discovered at Yale University.

Deoxymab 3E10 is an autoantibody originally identified in models of lupus. Unlike normal antibodies that bind to foreign cells (eg pathogens) or aberrant cells (eg cancer cells) and trigger an immune response, autoantibodies bind to normal cells. Of particular interest with Deoxymab 3E10 is that whilst most antibodies bind to markers on the surface of cells, Deoxymab 3E10 penetrates cells' nuclei and binds directly to DNA. Having bound to the DNA, Deoxymab 3E10 inhibits DNA repair and damages DNA. Normal cells repair DNA damage utilizing intact DNA repair processes, however Deoxymab 3E10 can kill cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. As well as showing single agent therapeutic potential, Deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 which is significantly more effective than the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form of PAT-DX1-NP towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants and xenograft models. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.



-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media and IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.